Practice gaps and barriers to optimal care of hematologic malignancies in the United States

Suzanne Murray, Kevin L. Obholz, Andrew D. Bowser, Jim Mortimer, Patrice Lazure, Eric Peterson, James Olen Armitage, B. Douglas Smith

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Treating patients with hematologic malignancies can be challenging for physicians because of the rapidly evolving standards of care and relatively low incidence of these diseases. Objective To identify clinical challenges among hematologists and medical oncologists regarding the provision of care to patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), or B-cell lymphomas. Methods Hematologists and medical oncologists in active practice in the United States and who have a case load of . 1 patient a year with CML, ALL, or B-cell lymphoma were recruited. The initial qualitative phase consisted of an online case-based survey followed by an interview exploring the contextual and behavioral factors that infuence treatment decisions (n = 27). The analysis of qualitative data then informed a quantitative phase, in which 121 participants completed an online survey composed of case vignettes, multiple choice, and semantic differential rating scale questions. The respondents-f answers were compared with recommendations from treatment guidelines and faculty experts. Results A higher frequency of bone marrow biopsies was reported compared with expert faculty recommendations by 74% of oncologists. Many respondents failed to recognize the clinical relevance of BCR-ABL mutations other than T315I. Respondents reported perceiving diffculties in individualizing treatment and interpreting response to treatment in patients with ALL and B-cell lymphomas. Fewer than 30% of respondents recognized the mechanisms of action of 5 of the 9 promising investigational agents presented. Limitations Participant self-selection bias is a possibility because participation was voluntary. Practice gaps are not based on clinical data, but hypothetical case situations and self-report. Conclusions Findings from this study can guide education to address the identifed challenges in caring for patients with hematologic malignancies and improving patient care. Funding This needs assessment was fnancially supported with an educational research grant from Pfzer Medical Education Group to the Annenberg Center for Health Sciences at Eisenhower.

Original languageEnglish (US)
Pages (from-to)329-338
Number of pages10
JournalJournal of Community and Supportive Oncology
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2014

Fingerprint

Hematologic Neoplasms
B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Patient Care
Semantic Differential
Training Support
Needs Assessment
Selection Bias
Therapeutics
Standard of Care
Medical Education
Self Report
Surveys and Questionnaires
Professional Practice Gaps
Bone Marrow
Guidelines
Interviews
Physicians
Biopsy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Murray, S., Obholz, K. L., Bowser, A. D., Mortimer, J., Lazure, P., Peterson, E., ... Smith, B. D. (2014). Practice gaps and barriers to optimal care of hematologic malignancies in the United States. Journal of Community and Supportive Oncology, 12(9), 329-338. https://doi.org/10.12788/jcso.0073

Practice gaps and barriers to optimal care of hematologic malignancies in the United States. / Murray, Suzanne; Obholz, Kevin L.; Bowser, Andrew D.; Mortimer, Jim; Lazure, Patrice; Peterson, Eric; Armitage, James Olen; Smith, B. Douglas.

In: Journal of Community and Supportive Oncology, Vol. 12, No. 9, 01.09.2014, p. 329-338.

Research output: Contribution to journalArticle

Murray, S, Obholz, KL, Bowser, AD, Mortimer, J, Lazure, P, Peterson, E, Armitage, JO & Smith, BD 2014, 'Practice gaps and barriers to optimal care of hematologic malignancies in the United States', Journal of Community and Supportive Oncology, vol. 12, no. 9, pp. 329-338. https://doi.org/10.12788/jcso.0073
Murray, Suzanne ; Obholz, Kevin L. ; Bowser, Andrew D. ; Mortimer, Jim ; Lazure, Patrice ; Peterson, Eric ; Armitage, James Olen ; Smith, B. Douglas. / Practice gaps and barriers to optimal care of hematologic malignancies in the United States. In: Journal of Community and Supportive Oncology. 2014 ; Vol. 12, No. 9. pp. 329-338.
@article{9245473eb16f44e1a43aa2b2e9f0c1e2,
title = "Practice gaps and barriers to optimal care of hematologic malignancies in the United States",
abstract = "Background Treating patients with hematologic malignancies can be challenging for physicians because of the rapidly evolving standards of care and relatively low incidence of these diseases. Objective To identify clinical challenges among hematologists and medical oncologists regarding the provision of care to patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), or B-cell lymphomas. Methods Hematologists and medical oncologists in active practice in the United States and who have a case load of . 1 patient a year with CML, ALL, or B-cell lymphoma were recruited. The initial qualitative phase consisted of an online case-based survey followed by an interview exploring the contextual and behavioral factors that infuence treatment decisions (n = 27). The analysis of qualitative data then informed a quantitative phase, in which 121 participants completed an online survey composed of case vignettes, multiple choice, and semantic differential rating scale questions. The respondents-f answers were compared with recommendations from treatment guidelines and faculty experts. Results A higher frequency of bone marrow biopsies was reported compared with expert faculty recommendations by 74{\%} of oncologists. Many respondents failed to recognize the clinical relevance of BCR-ABL mutations other than T315I. Respondents reported perceiving diffculties in individualizing treatment and interpreting response to treatment in patients with ALL and B-cell lymphomas. Fewer than 30{\%} of respondents recognized the mechanisms of action of 5 of the 9 promising investigational agents presented. Limitations Participant self-selection bias is a possibility because participation was voluntary. Practice gaps are not based on clinical data, but hypothetical case situations and self-report. Conclusions Findings from this study can guide education to address the identifed challenges in caring for patients with hematologic malignancies and improving patient care. Funding This needs assessment was fnancially supported with an educational research grant from Pfzer Medical Education Group to the Annenberg Center for Health Sciences at Eisenhower.",
author = "Suzanne Murray and Obholz, {Kevin L.} and Bowser, {Andrew D.} and Jim Mortimer and Patrice Lazure and Eric Peterson and Armitage, {James Olen} and Smith, {B. Douglas}",
year = "2014",
month = "9",
day = "1",
doi = "10.12788/jcso.0073",
language = "English (US)",
volume = "12",
pages = "329--338",
journal = "Journal of Community and Supportive Oncology",
issn = "2330-7749",
publisher = "Frontline Medical Communications",
number = "9",

}

TY - JOUR

T1 - Practice gaps and barriers to optimal care of hematologic malignancies in the United States

AU - Murray, Suzanne

AU - Obholz, Kevin L.

AU - Bowser, Andrew D.

AU - Mortimer, Jim

AU - Lazure, Patrice

AU - Peterson, Eric

AU - Armitage, James Olen

AU - Smith, B. Douglas

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background Treating patients with hematologic malignancies can be challenging for physicians because of the rapidly evolving standards of care and relatively low incidence of these diseases. Objective To identify clinical challenges among hematologists and medical oncologists regarding the provision of care to patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), or B-cell lymphomas. Methods Hematologists and medical oncologists in active practice in the United States and who have a case load of . 1 patient a year with CML, ALL, or B-cell lymphoma were recruited. The initial qualitative phase consisted of an online case-based survey followed by an interview exploring the contextual and behavioral factors that infuence treatment decisions (n = 27). The analysis of qualitative data then informed a quantitative phase, in which 121 participants completed an online survey composed of case vignettes, multiple choice, and semantic differential rating scale questions. The respondents-f answers were compared with recommendations from treatment guidelines and faculty experts. Results A higher frequency of bone marrow biopsies was reported compared with expert faculty recommendations by 74% of oncologists. Many respondents failed to recognize the clinical relevance of BCR-ABL mutations other than T315I. Respondents reported perceiving diffculties in individualizing treatment and interpreting response to treatment in patients with ALL and B-cell lymphomas. Fewer than 30% of respondents recognized the mechanisms of action of 5 of the 9 promising investigational agents presented. Limitations Participant self-selection bias is a possibility because participation was voluntary. Practice gaps are not based on clinical data, but hypothetical case situations and self-report. Conclusions Findings from this study can guide education to address the identifed challenges in caring for patients with hematologic malignancies and improving patient care. Funding This needs assessment was fnancially supported with an educational research grant from Pfzer Medical Education Group to the Annenberg Center for Health Sciences at Eisenhower.

AB - Background Treating patients with hematologic malignancies can be challenging for physicians because of the rapidly evolving standards of care and relatively low incidence of these diseases. Objective To identify clinical challenges among hematologists and medical oncologists regarding the provision of care to patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), or B-cell lymphomas. Methods Hematologists and medical oncologists in active practice in the United States and who have a case load of . 1 patient a year with CML, ALL, or B-cell lymphoma were recruited. The initial qualitative phase consisted of an online case-based survey followed by an interview exploring the contextual and behavioral factors that infuence treatment decisions (n = 27). The analysis of qualitative data then informed a quantitative phase, in which 121 participants completed an online survey composed of case vignettes, multiple choice, and semantic differential rating scale questions. The respondents-f answers were compared with recommendations from treatment guidelines and faculty experts. Results A higher frequency of bone marrow biopsies was reported compared with expert faculty recommendations by 74% of oncologists. Many respondents failed to recognize the clinical relevance of BCR-ABL mutations other than T315I. Respondents reported perceiving diffculties in individualizing treatment and interpreting response to treatment in patients with ALL and B-cell lymphomas. Fewer than 30% of respondents recognized the mechanisms of action of 5 of the 9 promising investigational agents presented. Limitations Participant self-selection bias is a possibility because participation was voluntary. Practice gaps are not based on clinical data, but hypothetical case situations and self-report. Conclusions Findings from this study can guide education to address the identifed challenges in caring for patients with hematologic malignancies and improving patient care. Funding This needs assessment was fnancially supported with an educational research grant from Pfzer Medical Education Group to the Annenberg Center for Health Sciences at Eisenhower.

UR - http://www.scopus.com/inward/record.url?scp=84991690967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991690967&partnerID=8YFLogxK

U2 - 10.12788/jcso.0073

DO - 10.12788/jcso.0073

M3 - Article

VL - 12

SP - 329

EP - 338

JO - Journal of Community and Supportive Oncology

JF - Journal of Community and Supportive Oncology

SN - 2330-7749

IS - 9

ER -